Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 2.6/5
Laurus Labs (LAURUS IN)
Watchlist
Contact IR
62
Analysis
Health Care
•
India
Laurus Labs Limited researches, develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India and internationally. It offers APIs for anti-retroviral and hepatitis C; and APIs in oncology and other therapeutic areas. .
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Dr Agarwal's Health Care Ltd
•
23 Jan 2025 05:20
Dr Agarwal’s Healthcare Pre-IPO - Strong Revenue Growth Led by Expanding Network of Facilities
Dr Agarwal’s Healthcare is looking to raise about US$480m in its upcoming India IPO. In this note, we talk about the company’s historical performance.
Akshat Shah
Follow
1k Views
Share
bullish
•
Thematic (Sector/Industry)
•
22 Jan 2025 06:53
The Outlook of Indian Pharma Industry in Trump 2.0
Indian pharma poised for growth as Trump's "China Plus One" strategy opens doors for manufacturers, amid conflicting goals of boosting domestic...
Nimish Maheshwari
Follow
306 Views
Share
bullish
•
Thematic (Sector/Industry)
•
19 Jan 2025 00:30
APAC Healthcare Weekly (Jan 19)- Samsung Biologics, Daiichi Sankyo, Eisai, Sun Pharma, Biocon
APAC healthcare companies got approvals for new products as well as clinical trials. The companies continued with acquisitions and collaborations...
Tina Banerjee
Follow
462 Views
Share
bullish
•
Suven Pharmaceuticals
•
14 Jan 2025 09:30
Suven Pharmaceuticals (SUVENPHA IN): M&A to Expand Technical Capabilities and Enhance Scale
Suven Pharmaceuticals strengthens position in high-growth markets such as ADCs and Oligonucleotides with acquisition of NJ Bio and Sapala Organics...
Tina Banerjee
Follow
382 Views
Share
bullish
•
Akums Drugs and Pharmaceuticals
•
16 Dec 2024 17:00
Akums Drugs and Pharmaceuticals: Limited Downside Is Seen, Long-Term Growth Story Intact
Akums Drugs shares are trading below IPO price post Q2FY25 results, but the company is well-positioned for long-term growth. Share price reaction...
Tina Banerjee
Follow
535 Views
Share
First
Previous
1
2
3
4
5
6
7
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.55.3
x